GO
Loading...

Dendreon CEO: Oncology Investments

Tuesday, 10 Jan 2012 | 11:17 AM ET

Dendreon's revenues for its solo product, Provenge, has more than tripled from a year ago. Insight on the drug's treatment of prostate cancer and an outlook on the healthcare sector, with Mitchell Gold, Dendreon president/CEO.